Cargando…

Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells

SIMPLE SUMMARY: Breast cancer cells typically metastasize to bone, where their interaction with bone remodeling cell types enhances metastatic outgrowth and osteolytic bone destruction. The respective knowledge is largely based on xenograft models, where human breast cancer cells are injected into i...

Descripción completa

Detalles Bibliográficos
Autores principales: Brylka, Laura, Jähn-Rickert, Katharina, Baranowsky, Anke, Neven, Mona, Horn, Michael, Yorgan, Timur, Wikman, Harriet, Werner, Stefan, Lübke, Andreas, Amling, Michael, Busse, Björn, Pantel, Klaus, Schinke, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833437/
https://www.ncbi.nlm.nih.gov/pubmed/35158823
http://dx.doi.org/10.3390/cancers14030556
_version_ 1784648941355139072
author Brylka, Laura
Jähn-Rickert, Katharina
Baranowsky, Anke
Neven, Mona
Horn, Michael
Yorgan, Timur
Wikman, Harriet
Werner, Stefan
Lübke, Andreas
Amling, Michael
Busse, Björn
Pantel, Klaus
Schinke, Thorsten
author_facet Brylka, Laura
Jähn-Rickert, Katharina
Baranowsky, Anke
Neven, Mona
Horn, Michael
Yorgan, Timur
Wikman, Harriet
Werner, Stefan
Lübke, Andreas
Amling, Michael
Busse, Björn
Pantel, Klaus
Schinke, Thorsten
author_sort Brylka, Laura
collection PubMed
description SIMPLE SUMMARY: Breast cancer cells typically metastasize to bone, where their interaction with bone remodeling cell types enhances metastatic outgrowth and osteolytic bone destruction. The respective knowledge is largely based on xenograft models, where human breast cancer cells are injected into immunocompromised mice. Importantly, however, whereas skeletal analyses in these animals are usually restricted to hindlimb bones, human skeletal metastases are far more frequent in the spine. Therefore, our study addressed the question, if breast cancer cells injected into immunocompromised mice would also metastasize to the spine, and if this process is influenced by the amount of trabecular bone. We injected an established breast cancer cell line into immunocompromised mice with or without a transgene causing severe osteoporosis. Importantly, we found more tumor cell clusters of different size in spine sections than in femora, but the presence of the transgene did not affect their spreading and metastatic outgrowth. ABSTRACT: Breast cancer cells frequently metastasize to bone, where their interaction with bone remodeling cell types enhances osteolytic bone destruction. Importantly, however, whereas skeletal analyses of xenograft models are usually restricted to hindlimb bones, human skeletal metastases are far more frequent in the spine, where trabecular bone mass is higher compared to femur or tibia. Here, we addressed whether breast cancer cells injected into immunocompromised mice metastasize to the spine and if this process is influenced by the amount of trabecular bone. We also took advantage of mice carrying the Col1a1-Krm2 transgene, which display severe osteoporosis. After crossing this transgene into the immunocompromised NSG background we injected MDA-MB-231-SCP2 breast cancer cells and analyzed their distribution three weeks thereafter. We identified more tumor cells and clusters of different size in spine sections than in femora, which allowed influences on bone remodeling cell types to be analyzed by comparing tumor-free to tumor-burdened areas. Unexpectedly, the Col1a1-Krm2 transgene did not affect spreading and metastatic outgrowth of MDA-MB-231-SCP2 cells, suggesting that bone tumor interactions are more relevant at later stages of metastatic progression.
format Online
Article
Text
id pubmed-8833437
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88334372022-02-12 Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells Brylka, Laura Jähn-Rickert, Katharina Baranowsky, Anke Neven, Mona Horn, Michael Yorgan, Timur Wikman, Harriet Werner, Stefan Lübke, Andreas Amling, Michael Busse, Björn Pantel, Klaus Schinke, Thorsten Cancers (Basel) Article SIMPLE SUMMARY: Breast cancer cells typically metastasize to bone, where their interaction with bone remodeling cell types enhances metastatic outgrowth and osteolytic bone destruction. The respective knowledge is largely based on xenograft models, where human breast cancer cells are injected into immunocompromised mice. Importantly, however, whereas skeletal analyses in these animals are usually restricted to hindlimb bones, human skeletal metastases are far more frequent in the spine. Therefore, our study addressed the question, if breast cancer cells injected into immunocompromised mice would also metastasize to the spine, and if this process is influenced by the amount of trabecular bone. We injected an established breast cancer cell line into immunocompromised mice with or without a transgene causing severe osteoporosis. Importantly, we found more tumor cell clusters of different size in spine sections than in femora, but the presence of the transgene did not affect their spreading and metastatic outgrowth. ABSTRACT: Breast cancer cells frequently metastasize to bone, where their interaction with bone remodeling cell types enhances osteolytic bone destruction. Importantly, however, whereas skeletal analyses of xenograft models are usually restricted to hindlimb bones, human skeletal metastases are far more frequent in the spine, where trabecular bone mass is higher compared to femur or tibia. Here, we addressed whether breast cancer cells injected into immunocompromised mice metastasize to the spine and if this process is influenced by the amount of trabecular bone. We also took advantage of mice carrying the Col1a1-Krm2 transgene, which display severe osteoporosis. After crossing this transgene into the immunocompromised NSG background we injected MDA-MB-231-SCP2 breast cancer cells and analyzed their distribution three weeks thereafter. We identified more tumor cells and clusters of different size in spine sections than in femora, which allowed influences on bone remodeling cell types to be analyzed by comparing tumor-free to tumor-burdened areas. Unexpectedly, the Col1a1-Krm2 transgene did not affect spreading and metastatic outgrowth of MDA-MB-231-SCP2 cells, suggesting that bone tumor interactions are more relevant at later stages of metastatic progression. MDPI 2022-01-22 /pmc/articles/PMC8833437/ /pubmed/35158823 http://dx.doi.org/10.3390/cancers14030556 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Brylka, Laura
Jähn-Rickert, Katharina
Baranowsky, Anke
Neven, Mona
Horn, Michael
Yorgan, Timur
Wikman, Harriet
Werner, Stefan
Lübke, Andreas
Amling, Michael
Busse, Björn
Pantel, Klaus
Schinke, Thorsten
Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells
title Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells
title_full Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells
title_fullStr Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells
title_full_unstemmed Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells
title_short Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells
title_sort spine metastases in immunocompromised mice after intracardiac injection of mda-mb-231-scp2 breast cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833437/
https://www.ncbi.nlm.nih.gov/pubmed/35158823
http://dx.doi.org/10.3390/cancers14030556
work_keys_str_mv AT brylkalaura spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT jahnrickertkatharina spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT baranowskyanke spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT nevenmona spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT hornmichael spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT yorgantimur spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT wikmanharriet spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT wernerstefan spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT lubkeandreas spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT amlingmichael spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT bussebjorn spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT pantelklaus spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells
AT schinkethorsten spinemetastasesinimmunocompromisedmiceafterintracardiacinjectionofmdamb231scp2breastcancercells